Monthly run archive / October 2026

Modern Formula Full Universe Top 40

October 4, 2026 research cycle. Model entry: October 5, 2026 close.

This October research version is being archived after the model entry date. Results are a retrospective model comparison, not evidence of a portfolio published before entry. The run date labels the research cycle; the actual public timestamp is the hosting deployment record.

Run IDMFI-2026-10-04-v0.1
Prepared (UTC)2026-10-12T01:54:49+00:00
MethodologyModern Formula v0.1
Portfolio40 names

First worksheet; original rank order.

Model performance

Portfolio and benchmark.

Portfolio closes: October 5, 2026. Benchmark close: October 5, 2026.

Weighted portfolio return
0.00%
VTI return
0.00%
Difference vs. VTI
+0.00 pp

Price returns from the entry close, before dividends, fees, and taxes. Splits and other corporate actions require review. Each portfolio is tracked separately; overlapping holdings are not combined into a single track record.

Top-40 model portfolio

Holdings and entry prices.

Per our target weighting, this run uses the top 40 ranked names and applies rank-weighted model allocations. Ranks 1-12, their prices and individual returns, and exact allocations are reserved for members.

Membership access   Download public entry snapshot CSV

40 of 40 entry prices recorded. Latest portfolio closes: October 5, 2026.

RankTickerTierAllocationEntry dateEntry priceLatest closePrice return
1 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
2 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
3 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
4 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
5 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
6 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
7 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
8 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
9 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
10 Subscriber Only Core overweight Member Only October 5, 2026 close Member Only Member Only Member Only
11 Subscriber Only Core Member Only October 5, 2026 close Member Only Member Only Member Only
12 Subscriber Only Core Member Only October 5, 2026 close Member Only Member Only Member Only
13 OSPN Core Member Only October 5, 2026 close $18.42 $18.42 0.00%
14 PBI Core Member Only October 5, 2026 close $16.81 $16.81 0.00%
15 PFE Core Member Only October 5, 2026 close $27.41 $27.41 0.00%
16 ADEA Core Member Only October 5, 2026 close $26.07 $26.07 0.00%
17 CHCI Core Member Only October 5, 2026 close $19.17 $19.17 0.00%
18 THC Core Member Only October 5, 2026 close $259.47 $259.47 0.00%
19 BBY Core Member Only October 5, 2026 close $87.39 $87.39 0.00%
20 BMY Core Member Only October 5, 2026 close $58.81 $58.81 0.00%
21 DLO Standard Member Only October 5, 2026 close $14.52 $14.52 0.00%
22 IBEX Standard Member Only October 5, 2026 close $43.33 $43.33 0.00%
23 INCY Standard Member Only October 5, 2026 close $114.13 $114.13 0.00%
24 LAUR Standard Member Only October 5, 2026 close $38.51 $38.51 0.00%
25 SJM Standard Member Only October 5, 2026 close $116.23 $116.23 0.00%
26 WEX Standard Member Only October 5, 2026 close $172.48 $172.48 0.00%
27 ZD Standard Member Only October 5, 2026 close $55.98 $55.98 0.00%
28 MLI Standard Member Only October 5, 2026 close $62.97 $62.97 0.00%
29 ADUS Standard Member Only October 5, 2026 close $112.98 $112.98 0.00%
30 AUPH Standard Member Only October 5, 2026 close $15.72 $15.72 0.00%
31 EAT Starter Member Only October 5, 2026 close $194.16 $194.16 0.00%
32 GFF Starter Member Only October 5, 2026 close $94.09 $94.09 0.00%
33 DSP Starter Member Only October 5, 2026 close $12.14 $12.14 0.00%
34 SIG Starter Member Only October 5, 2026 close $100.89 $100.89 0.00%
35 BLBD Starter Member Only October 5, 2026 close $57.03 $57.03 0.00%
36 CCSI Starter Member Only October 5, 2026 close $36.38 $36.38 0.00%
37 CVS Starter Member Only October 5, 2026 close $87.01 $87.01 0.00%
38 CRCT Starter Member Only October 5, 2026 close $6.47 $6.47 0.00%
39 RCMT Starter Member Only October 5, 2026 close $41.59 $41.59 0.00%
40 WLY Starter Member Only October 5, 2026 close $48.54 $48.54 0.00%

Opportunity notes

Why the top 15 ranked here.

The score measures fit with the opportunity framework, not a forecast of future returns. Commentary summarizes the supplied October research version. Notes for ranks 1-12 are reserved for members.

Rank 1 / 83.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 2 / 75 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 3 / 74.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 4 / 73 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 5 / 73 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 6 / 72.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 7 / 70 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 8 / 69.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 9 / 69 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 10 / 69 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 11 / 68.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 12 / 68.5 score

Subscriber Only

Detailed opportunity note reserved for members.

Rank 13 / 67.5 score

OSPN

OneSpan's recurring security software, growing annual recurring revenue, and financial resources support the opportunity. Higher guidance and the Build38 acquisition add potential, but operating income needs to keep pace with adjusted earnings. Legacy hardware decline, acquisition integration, and cash costs temper the apparent discount.

Rank 14 / 66 score

PBI

Pitney Bowes offers a turnaround case grounded in improving operating profit, cash generation, and debt reduction. The strategic review may create additional options, but the valuation does not assume a sale or treat the stock as merger arbitrage. Secular mail decline and remaining leverage still constrain long-term earnings value.

Rank 15 / 66 score

PFE

Pfizer's established pharmaceutical franchises and non-COVID growth support a discounted operating value case. Restructuring may help, but the thesis does not depend on a return to pandemic windfalls. Patent expiries, acquisition debt, and the ongoing cost of replacing the pipeline remain material risks.

Ranked research

October Top 40.

Download public ranking CSV

Show ranked research
RankTickerScoreBandOpportunity and risk
1 Subscriber Only 83.5 Strong MF fit Detailed thesis reserved for members.
2 Subscriber Only 75 Good candidate with hair Detailed thesis reserved for members.
3 Subscriber Only 74.5 Good candidate with hair Detailed thesis reserved for members.
4 Subscriber Only 73 Good candidate with hair Detailed thesis reserved for members.
5 Subscriber Only 73 Good candidate with hair Detailed thesis reserved for members.
6 Subscriber Only 72.5 Good candidate with hair Detailed thesis reserved for members.
7 Subscriber Only 70 Good candidate with hair Detailed thesis reserved for members.
8 Subscriber Only 69.5 Interesting but messy Detailed thesis reserved for members.
9 Subscriber Only 69 Interesting but messy Detailed thesis reserved for members.
10 Subscriber Only 69 Interesting but messy Detailed thesis reserved for members.
11 Subscriber Only 68.5 Interesting but messy Detailed thesis reserved for members.
12 Subscriber Only 68.5 Interesting but messy Detailed thesis reserved for members.
13 OSPN 67.5 Interesting but messy OneSpan's recurring security software, growing annual recurring revenue, and financial resources support the opportunity. Higher guidance and the Build38 acquisition add potential, but operating income needs to keep pace with adjusted earnings. Legacy hardware decline, acquisition integration, and cash costs temper the apparent discount.
14 PBI 66 Interesting but messy Pitney Bowes offers a turnaround case grounded in improving operating profit, cash generation, and debt reduction. The strategic review may create additional options, but the valuation does not assume a sale or treat the stock as merger arbitrage. Secular mail decline and remaining leverage still constrain long-term earnings value.
15 PFE 66 Interesting but messy Pfizer's established pharmaceutical franchises and non-COVID growth support a discounted operating value case. Restructuring may help, but the thesis does not depend on a return to pandemic windfalls. Patent expiries, acquisition debt, and the ongoing cost of replacing the pipeline remain material risks.
16 ADEA 65.5 Interesting but messy Adeia's patent licenses produce high-margin cash flow with limited physical capital needs, supported by renewals and semiconductor adoption. Contract timing, litigation costs, debt, and recurring operating expenses limit how much of adjusted earnings can be treated as dependable owner cash.
17 CHCI 65.5 Interesting but messy Comstock's property-management and development fees support a profitable, capital-light business with cash and no funded debt in the supplied research. Related-party concentration and project timing constrain reliability, while investment gains and tax benefits should be separated from recurring operating earnings.
18 THC 65.5 Interesting but messy Tenet's ambulatory-care operations, stronger cash flow, and repurchases support a continuing operating recovery. Leverage, reimbursement, and minority ownership in surgery centers mean consolidated earnings must be adjusted to determine the cash attributable to common shareholders.
19 BBY 65 Interesting but messy Best Buy retains a profitable retail-and-services franchise with capital returns and recovery potential. Electronics replacement cycles, competition, and promotions limit normalized margins, and temporary tariff refunds should not be counted as recurring earnings.
20 BMY 65 Interesting but messy Bristol Myers Squibb's growing commercial portfolio and higher guidance support substantial ongoing cash generation. Legacy patent erosion, acquisition spending, and necessary pipeline investment explain much of the discount and must remain in the valuation.
21 DLO 65 Interesting but messy dLocal's expanding payments platform and strong balance sheet support its operating value. Falling gross profit relative to payment volume and rising costs make rapid volume growth an incomplete measure of shareholder earnings, with emerging-market exposure adding risk.
22 IBEX 65 Interesting but messy IBEX combines revenue and earnings growth with cash generation and capital returns. Customer concentration, wage costs, and the potential for AI to replace outsourced service work limit the duration and valuation assigned to current earnings.
23 INCY 65 Interesting but messy Incyte's Jakafi and Opzelura franchises support recurring commercial cash flow. A noncash reimbursement adjustment and acquired research charges complicate reported results, while patent concentration and pipeline spending remain the main valuation constraints.
24 LAUR 65 Interesting but messy Laureate's established campuses and recurring enrollment in Mexico and Peru support cash earnings and capital returns. Currency exposure, tuition affordability, and education-sector regulation constrain the durability premium warranted by current growth.
25 SJM 65 Interesting but messy Smucker's established food and beverage brands support recurring demand and a potential earnings recovery. Hostess integration, debt, commodity costs, and mature categories remain constraints, and tariff refunds should be excluded from normalized earnings.
26 WEX 65 Interesting but messy WEX's fleet, travel, and benefits payments combine repeat business with operating leverage and repurchases. Fuel-price sensitivity, credit exposure, and financing liabilities require a more careful valuation than a simple comparison with debt-free software businesses.
27 ZD 65 Interesting but messy Ziff Davis's completed Connectivity sale strengthened financial flexibility and supported share repurchases. Value should combine continuing earnings with post-transaction cash, without counting the disposed business twice, while AI and search disruption remain risks for the remaining portfolio.
28 MLI 64.5 Interesting but messy Mueller Industries combines established manufacturing positions with cash resources and strong returns on capital. Copper pricing, construction demand, and acquisition contributions require normalized earnings rather than a valuation based on unusually favorable commodity margins.
29 ADUS 64 Interesting but messy Addus HomeCare's scale, recurring care demand, and operating growth support its acquisition-led model. Medicaid reimbursement, labor availability, and integration execution limit the value gap at the current price.
30 AUPH 64 Interesting but messy Aurinia's commercial LUPKYNIS franchise produces profits and cash flow, supported by a strong balance sheet and repurchases. Single-product dependence, patent duration, and continued growth spending constrain the multiple appropriate for those earnings.
31 EAT 64 Interesting but messy Brinker's Chili's recovery and substantial repurchases reflect genuine operating improvement. The valuation offers less protection than at the trough, so traffic, food and labor costs, leases, and fiscal-year comparability need to be reflected in sustainable earnings.
32 GFF 64 Interesting but messy Griffon's simplified portfolio, door-business cash flow, and repurchases support its value case. Housing demand and remaining debt are material risks, and disposed businesses' earnings should not be combined with the continuing company's capital structure.
33 DSP 63.5 Interesting but messy Viant's connected-TV growth, measurement capabilities, and balance sheet support operating potential. Stock compensation and a high reported operating-earnings multiple weaken the apparent adjusted-earnings bargain despite strong revenue growth.
34 SIG 63.5 Interesting but messy Signet Jewelers combines established jewelry brands, positive comparable sales, cash, and an accelerated repurchase program. Tariff refunds should be removed from normalized margins, while discretionary demand, lab-grown diamond pricing, inventory, and leases constrain the discount.
35 BLBD 63 Interesting but messy Blue Bird benefits from school-bus replacement demand and higher guidance. Acquisition contributions and accounting gains complicate reported growth, so the valuation should use recurring combined-company earnings while allowing for weaker legacy bookings and subsidy exposure.
36 CCSI 63 Interesting but messy Consensus Cloud's digital-fax and healthcare workflows generate recurring cash, with repurchases supporting per-share value. Legacy consumer decline, debt, and the durability of healthcare growth remain the principal limits on its operating valuation.
37 CVS 63 Interesting but messy CVS's integrated pharmacy and insurance operations offer recovery potential supported by improved guidance and operating cash flow. Medical-cost trends, regulation, and leverage remain the main risks, while subsidiary restructuring should be distinguished from the parent's continuing business.
38 CRCT 62.5 Interesting but messy Cricut's subscriptions, cash resources, and capital returns provide value support as hardware sales decline. Unusual items in operating profit and weaker product demand mean reported margin expansion should not be extrapolated as recurring growth.
39 RCMT 62.5 Interesting but messy RCM Technologies combines engineering and healthcare staffing earnings with revenue growth at a reasonable valuation. Slower gross-profit growth, receivables, debt, and disclosed internal-control weaknesses warrant scrutiny before treating reported growth as durable value creation.
40 WLY 62.5 Interesting but messy Wiley's research publishing supports recurring demand and cash generation, with restructuring providing potential value. Legacy pressure and weaker adjusted operating profit constrain the case, and one-time AI licensing agreements should not be valued as recurring subscriptions.

Benchmarks

Comparison baseline.

BenchmarkEntry dateEntry priceStatus
VTIOctober 5, 2026 close$380.60Started
Magic Formula Top 50 over $50MPending constituent list and entry prices

Publication ledger

Research version and record.

Research cycle
October 4, 2026
Entry date
October 5, 2026 close.
Latest dated source information
September 21, 2026
Publication timing
Prepared after entry. See the hosting deployment record for the actual public timestamp.
Source workbook
Consolidated_Oct-2026_FULL_UNIVERSE.xlsx
Source worksheet
Consolidated
Ranking CSV SHA-256
60f95baa09a72e1c9b58b7692348081882c36f4a81172e2bd0322487e23d9dcf
Portfolio CSV SHA-256
4905fad044f8ebbed0d881016d5889f3a8690e1ecb531b13329daaf3b647916d
Manifest
View publication manifest

Preserve the original publication and record any corrections with a new date. Portfolio closes can be updated separately from the archived research.